A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.
This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.
WASHINGTON, DC: Jayanta Bhattacharya, Director of the National Institutes of Health. (Photo by Andrew Harnik/Getty Images) Director of the National Institutes of Health, Jay Bhattacharya, recently ...
Initiate Moderna with a Hold rating at a $25 target price (lower than the current price), citing balanced risk-reward despite the advanced mRNA platform and robust pipeline. MRNA's near-term execution ...
NEW ALBANY, OH / ACCESSWIRE / April 16, 2024 / AmplifyBio, a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) focused on differentiating services ...
STONY BROOK, NY / ACCESSWIRE / July 13, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it has acquired ...
Integrating AI with advanced robotics to create self-driving labs (SDL) is a promising approach to tackling molecular discovery. A new SDL system, called LUMI-lab, combines large-scale molecular ...
The same groundbreaking technology that enabled rapid COVID-19 vaccine development is now poised to revolutionize medicine in ways that seemed impossible just a few years ago. Messenger RNA vaccines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results